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INTRODUCTION
It is estimated that more than 1100 drugs or herbal agents are associated with DILI.1 DILI 
can present as various forms of both acute and chronic liver disease and, although self-
limited in the majority of cases, can have more severe consequences, with approximately a 
10% case fatality or transplantation rate within the first 6 months of DILI onset and a 20% 
rate of progression to chronic liver injury.2–8 DILI remains the leading cause of acute liver 
failure (ALF) both in the United States and internationally.1–3,5,9,10 Geographic variation is 
common in the most frequently implicated agents1,9,11 for a variety of reasons, including 
host and environmental factors, such as xcessive alcohol and tobacco consumption, 
infection, pro-inflammatory states, and variations in circadian rhythm. Although host factors 
are much more robustly described across the body of literature, the environment promoting 
hepatotoxicity is an ever-expanding and in some instances unexplored field. Environmental 
factors are important considerations for both intrinsic, or dose-dependent DILI, and 
idiosyncratic DILI (iDILI). Intrinsic DILI, although more rare, occurs in individuals at the 
same toxic dose threshold.12,13 iDILI remains more problematic, less understood, and much 
more dependent on both environmental and genetic covariates to produce a milieu of 
susceptibility at the individual level. Currently available testing to both predict and diagnose 
iDILI in premarketing and postmarketing trials is largely ineffective14 and most cases of 
iDILI are discovered when medications are prescribed in much greater volume after 
regulatory approval.15 This review focuses on the available evidence supporting specific 
environmental factors (Box 1) and their influence on the likelihood and outcomes of DILI.
*Corresponding author. nchalasa@iu.edu. 
Disclosure: Dr N.P. Chalasani serves as a consultant to many pharmaceutical companies for both nonalcoholic steatohepatitis and drug 
hepatotoxicity, but none of them represents significant and direct conflict with this review article. Dr J.G. Stine has nothing to disclose.
HHS Public Access
Author manuscript
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
Published in final edited form as:
Clin Liver Dis. 2017 February ; 21(1): 103–113. doi:10.1016/j.cld.2016.08.008.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GEOGRAPHIC VARIATION
The World Health Organization (WHO) initially began the Programme for International 
Drug Monitoring (PDIM) in 1968 involving 10 countries, a majority of which were in the 
regions of Europe or North America (including the United States), in a collaborative effort to 
pool national data from spontaneous adverse event reporting systems.16 Ultimately, this 
collaboration led to the creation of VigiBase in the mid-1990s, a database system comprised 
of more than 7 million individual case safety reports that became accessible for medical 
research in 2012 and publically searchable in a limited fashion in 2015 (http://
www.vigisearch.org).16 This collaboration has expanded to more than 80 nations and 
currently includes the regions of Africa, Asia, and Latin America.16
In an analysis of VigiBase that spanned data from 2000 to 2009, Agaard and colleagues17 
found geographic variation in both frequency of adverse drug reaction (ADR) reporting as 
well as the type of medication associated with the ADR. Low-income countries, as defined 
by the World Bank, were less likely to report ADRs.17 Low-income countries reported a 
greater frequency of ADRs with antibiotics and antifungal and antiviral medications whereas 
ADRs were more common for immunomodulatory and antineoplastic drugs in high-income 
nations.17 The investigators postulated that ADR reporting was more a feature of income 
rather than actual geography and highlighted the need to improve ADR reporting rates in 
low-income nations, in particular African nations that contribute less than 1% of the total 
individual case safety report volume.18 Despite this, several important differences between 
African nations and all other countries in the WHO-PDIM are worth noting. African nations 
report DILI occurring on average in a younger population (18–44 years of age) compared 
with 45 to 64 years of age in the rest of the world, and 28% of all ADRs reported were 
attributable to antiviral medications used to treat HIV.18 Further highlighting geographic 
differences in DILI, an analysis of VigiBase by Suzuki and colleagues,19 limited to the 
United States, England, and Sweden, found that of the 385 unique medications reported, 
only 9.7% appeared in all 3 registries. Of the 47 drugs subjected to regulatory action, only 6 
were found in all 3 regions.19 Reports from European centers were also more homogenous 
compared with reports from the United States.19 A recent report from a single center in India 
that does not perform liver transplantation incorporating 303 cases of hepatotoxicity from 
1997 to 2008 found that 58% were attributable to tuberculosis agents10; strikingly, no cases 
of APAP toxicity were reported. Despite this, a 17.3% case-fatality rate was reported, owing 
largely to ALF from anti-TB drugs.10
EXCESSIVE ALCOHOL CONSUMPTION
Although excessive alcohol consumption has historically been incorporated into causality 
assessment, namely that put forth by the Council for International Organizations of Medical 
Sciences,12 only a handful of medications have been demonstrated to have increased 
hepatotoxic potential in the setting of excessive alcohol use, namely APAP, highly active 
antiretroviral therapy (HAART), halothane, and anti-TB therapy with isoniazid or 
methotrexate.12
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Coined alcohol-APAP syndrome (AAS), the risk of APAP toxicity in the setting of alcohol 
use has been well described since the 1980s.20–24 AAS is related to CYP2E1 induction as 
well as glutathione depletion directly attributable to the toxic effects of alcohol.22 
Concurrent malnutrition can predispose a patient to liver injury in this setting through 
impaired glucuronidation.22,25,26
The chronicity of consumption of alcohol may also a role in hepatotoxicity. In a series of 
645 patients with singe-dose APAP toxicity, Schmidt and colleagues20 found that chronic 
alcohol abuse was an independent predictor for mortality while controlling for other 
confounding factors (odds ratio [OR] 3.52; 95% CI, 1.78–6.97), including renal failure, 
which has previously been implicated in the increased mortality in this patient population.27 
When APAP overdose superimposed on chronic alcohol consumption (defined as >21 drinks 
per week for men and >14 drinks per week for women) presents with acute renal failure with 
creatinine greater than 3.0 mg/dL, prothrombin time greater than 100 seconds, and grades 
III–IV portosystemic encephalopathy, the prognosis is uniformly fatal.27 In a prospective 
nested case-control study of 150 patients with anti-TB drugs, associated DILI drawn from an 
overall cohort of 3900 patients exposed to anti-TB drugs, Gaude and colleagues28 found that 
42.2% of DILI cases had significant chronic alcohol consumption and that alcohol abuse 
was predictive of DILI risk on adjusted multivariable analysis.
On the other hand, acute alcohol ingestion may be protective against hepatotoxicity. In 
animal models, acute alcohol ingestion inhibits CYP2E1 oxidation of APAP, ultimately 
resulting in a lower level of N-acetyl-p-benzoquinone imine, the reactive metabolite 
responsible for the known hepatotoxic potential.29 This has been corroborated in human 
observational study because acute ingestion of alcohol in alcoholic patients was associated 
with a profound reduction in risk (OR 0.08; 95% CI, 0.01–0.66) of APAP hepatotoxicity.20
Alcohol is also thought to play a role in hepatotoxicity attributed to HAART when used for 
the treatment of HIV (namely protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors).30 Excessive alcohol use may also lead to decreased treatment efficacy and 
acceleration of HIV to AIDS through changes in CYP2E1 and CYP3A4 activity.31 This is 
important to recognize given that approximately one-fourth of patients with newly diagnosed 
HIV are alcohol dependent.30 With the widespread use of similar classes of medications to 
treat chronic hepatitis C virus (HCV) as a part of the new all-oral direct-acting antiviral 
regimens and the overlap with comorbid polysubstance abuse, including alcohol, it will be 
interesting to see if alcohol consumption with the direct-acting antivirals predisposes to 
either hepatotoxicity or loss of treatment effect, because reports of the hepatotoxic potential 
of these medications have already surfaced.32 There have been several reports of increased 
hepatotoxicity with HAART in patients with HIV/HCV coinfection who abuse alcohol.33,34
Alcohol abuse in heavy quantities is associated with accelerated fibrosis in patients who are 
prescribed chronic immunosuppressive therapy with the antimetabolite methotrexate.35,36 In 
a meta-analysis of 15 studies, including 636 patients, Whiting-O’Keefe and colleagues36 
found the pooled risk of advanced fibrosis was 17.8% versus 4.5% (P = .003) in heavy 
drinkers, which was defined as greater than or equal to 100 g of alcohol per week. This 
population also had histologic progression more frequently (73% vs 26%, P = .002).36 In 
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accordance with expert opinion, pretreatment liver biopsy is often considered on an 
individual basis in patients with a history of heavy alcohol consumption to assess for 
advanced fibrosis prior to initiation of methotrexate.
Despite the evidence put forth from the aforementioned studies, several large registries have 
not validated the risk of excessive alcohol consumption and any association with DILI.5,11,37 
A majority of patients in a Spanish registry of 461 subjects with DILI had alcohol 
consumption less than 40 g/d.
SMOKING
In contrast to the available body of evidence for excessive alcohol and its role in 
hepatotoxicity development, the literature describing tobacco smoking is much less 
prevalent and is based solely on observational studies. A Brazilian series of 131 subjects 
treated with anti-TB drugs found a decreased risk of developing anti-TB DILI in active 
smokers compared with lifelong nonsmokers (OR 0.28; 95 CI, 0.11–0.64; P<.01).38 
Additionally, the investigators found that CYP2E1, despite known to be induced by 
smoking, was not associated with hepatotoxicity, confirming previous reports.39,40 CYP1A2 
may also be up-regulated by smoking without known clinically relevant hepaotoxicity.40 A 
single-center experience in Denmark of 602 patients with APAP toxicity found that 70% 
were daily tobacco users and this was predictive of severity of injury (diagnosed by 
significantly higher peak aminotransferase and international normalized ratio levels) as well 
as all-cause mortality (OR 3.64; 95% CI, 1.23–10.75).41 On the other hand, Wada and 
colleagues42 found that, of the 33 patients in a series of 123 patients with prostate cancer 
treated with the antiandrogenic drug flutamide, which is metabolized by both CYP1A2 and 
CYP3A enzymes, smoking was associated with significantly lower odds of hepatotoxicity.
INFECTION AND INFLAMMATION
Infection and inflammation, through innate immune responses to the invasion of the body by 
foreign agents, including bacteria, viruses, and fungus, may predispose a patient to either 
intrinsic DILI or iDILI. The risk of intrinsic, or dose-dependent, DILI is due largely to a left 
shift in the dose-response curve, thereby sensitizing hepatocytes to injury,43–45 through a 
complex proinflammatory cascade involving pathogen-associated molecular patterns, 
damage-associated molecular patterns, Toll-like receptors, Kupffer cells, tumor necrosis 
factor (TNF)-α, natural killer cells, interferon gamma, polymorphonuclear neutrophils, 
endothelial cells, prostaglandins, dendritic and stellate cells, and both the coagulation46 and 
complement systems, the specifics of which are beyond the scope of this review but have 
been described in detail by other investigators.13
Animal models using both lipopolysaccharide (LPS) and TNF-α exposed mice have found 
that these models of inflammation predispose to intrinsic DILI from both APAP and 
trovafloxacin.43,45 The timing of LPS administration varied in hepatotoxicity risk in APAP 
animal models, where LPS given 2 hours before APAP had significantly greater risk 
compared with LPS administration 24 hours prior to APAP.47 Animal models investigating 
the exogenous stress of cocaine administration have found that LPS augments the injury 
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from cocaine.48 Because both TNF-α and LPS are surrogates for circulating endotoxemia, it 
is surprising that advanced fibrosis and cirrhosis have not been49 documented to 
significantly increase the risk of DILI for a large number of medications; however, most 
medications have not been largely studied in patients with cirrhosis and dose adjustment for 
cirrhosis is often lacking in the prescribing information, despite changes in both 
pharmacokinetics and pharmacodynamics in this special population.49
Inflammation and infection also seem to play a greater role in iDILI and ultimately hepatic 
necrosis. Similar to intrinsic DILI, a majority of evidence is afforded from animal models. In 
the setting of LPS-induced endotoxemia, various medications, such as amiodarone, 
diclofenac, halothane, ranitidine, sulindac, and trovafloxacin, have been implicated in iDILI.
13,44,50–53
 Proinflammatory TNF-α also plays a role in iDILI because blocking TNF-α with 
pentoxifylline in several of these animal models proved effective in decreasing the severity 
of liver injury.44,50 The coagulation system is also activated in periods of acute inflammation 
and the balance between procoagulation and anticoagulation shifts toward thrombotic risk. 
LPS administration in animal models has led to increased levels of circulating plasminogen 
activator inhibitor 1 (PAI-1) and ultimately increased fibrin deposition in experimentally 
induced iDILI.54 PAI-1 may also play a role in the mechanism of intrinsic DILI form 
APAP46 and has been implicated in other inflammatory processes in the liver (namely 
nonalcoholic steatohepatitis).55 Furthermore, anticoagulation with heparin-reduced fibrin 
deposition and thrombin generation has been shown to lead to an attenuation of the 
hepatotoxic response,54 and treatment with tissue plasminogen activator (streptokinase) has 
been shown to reduce hepatotoxicity through a similar mechanism.56 Collectively, these 
animal models suggest that activation of the coagulation cascade leads to fibrin deposition 
and ultimately tissue hypoxia and worsening cellular death and necrosis, findings that 
warrant validation in human models where to date, the majority of serum testing has focused 
on drug-induced ALF and the role of microparticles.57 These membrane fragments of 0.1 
μm to 1.0 μm are derived from systemic inflammation and seem predictive of worse clinical 
outcomes in ALF, including those cases that are drug-induced.
CIRCADIAN RHYTHM AND THE HEPATIC CLOCK
Circadian time is an important process affecting both the pharmacokinetic as well as the 
pharmacodynamic properties of drugs across a 24-hour span.58 This so-called hepatic clock 
is driven by the central suprachiasmatic nucleus of the hypothalamus, which organizes the 
majority of circadian change at the cellular level.59 Fasting-feeding cycles in association 
with rest-activity rhythms help synchronize the hepatic clock, including the control of 
xenobiotic detoxification, in effect allowing for the temporal coordination of metabolism.
59,60
Although the available data are mostly from animal models investigating anti-TB 
medications and APAP,58,61–66 there have been extensions in the human population.67 
Through lipid peroxidation inducing mitochondrial toxicity, Souayed and colleagues58 found 
that toxic doses of isoniazid in mice at 1 and 9 zeitgeber time produced severe hepatic 
necrosis whereas dosing at 17 zeitgeber time did not. Deletion of circadian gene Per1 has 
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been shown to change the hepatotoxic risk from alcohol,62 whereas mPer2 has a role in the 
diurnal variation of APAP toxicity, both in mice.64
Patients taking APAP may also be predisposed due to hepatotoxicity due to 24-hour 
circadian variation.59,68 This may be due in part to the normal pattern of intermittent fasting 
states over a 24-hour period because during times of fasting,68 glutathione levels are known 
to drop,69,70 thus potentially decreasing a protective mechanism that normally prevents 
toxicity from APAP. Fasting states are also known to disrupt detoxification of anti-TB drugs 
leading to change in the CYP system, predisposing to liver toxicity.71,72
Although recommendations for timing of medication administration or dose reduction based 
on circadian rhythm and resultant drug metabolism effects is a long way off, these results are 
nonetheless collectively intriguing. APAP is generally taken during times of illness, namely 
fever or pain, both of which are associated with fasting states. More prospective study in 
human based populations is needed.
GUT MICROBIOME
The role of the gut microbiome is also being explored for its potential as a means to protect 
against APAP-induced and antimicrobial DILI.73–75 Possamai and colleagues73 found that 
when given an intravenous dose of hepatotoxic APAP, the urinary ratio of APAP-
sulphate:glucuronide was significantly different when comparing the conventionally housed 
mice to the germ-free mice because the germ-free mice were found to have higher 
concentrations; however, interruption of Toll-like receptor 4 signaling was also protective, 
leading the investigators to conclude that the microbiome itself may play a role but not offer 
the complete explanation for the observed differences. Xue and colleagues74 recently 
published their experience with 3,4-dihydroxyphenylacetic acid, a microbiota-derived 
metabolite, and its protective role through nuclear factor–erythroid 2-related factor when 
exposed to toxic levels of APAP, also in mice. Using urinary bile acids as a surrogate for 
antimicrobial hepatoxicity, Bhowmik and colleagues75 demonstrated that gut microbiota 
may play a significant role in bile acid homeostasis and metabolism because germ-free mice 
had elevated levels of cholic acid and α-muricholic acid/β-muricholic acid, which could 
predispose to hepatotoxicity in this sterile environment. The authors are unaware of any 
studies in human models investigated the role of the gut microbiome in predisposing or 
preventing DILI.
ENVIRONMENTAL POLLUTION
Exposure through an environment rich with pollution can place an individual at risk for 
hepatotoxicity and although the majority of liver injury is fairly benign with a modest 
elevation in liver-associated enzymes,76 rare instances of fatal hepatitis have been reported.
77
 In a retrospective case-control study of 247 subjects, D’Andrea and Reddy76 found 
significantly elevated liver-associated enzymes in cases of oil spill clean-up workers exposed 
to potential toxins from the Gulf oil spill along the coast of Louisiana, perhaps directly 
attributable to benzenes and paraphenols. Exposure to organic pesticides, such as 
chlorpyrifos, endosulfan, and pyrethroids,78,79 often through wastewater exposure,80 has 
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also been associated with hepatotoxicity. The importance of this cannot be understated, 
because a prospective study by Cecchi and colleagues81 of 97 women living in the rural Rio 
Negro province of Argentina found a predominant increase in alanine aminotransferase 
(ALT) values in the second trimester of pregnancy, with ALT greater than aspartate 
aminotransferase (AST). These laboratory abnormalities were not predictive, however, of 
worse maternal-fetal outcomes in the immediate postpartum period as measured by 
incidence rates of premature birth and miscarriage, and no cases of fatal hepatitis or nonfatal 
ALF were reported.81
SUMMARY
The role of environmental factors in predisposing a patient to both intrinsic DILI and iDILI 
remains a work in progress. Through the evolution of animal models, the complicated 
interaction between modifiable risk factors, such as tobacco smoking, excessive alcohol 
consumption, intestinal microbiome, environmental pollutants, and proinflammatory and/or 
hypercoagulable states, is only beginning to be understood. Although much research 
attention remains focused to identifying specific individual risk factors with genome-wide 
association studies, perhaps more attention should be focused on confirming the 
environmental observations from these animal models in human-based studies, both on 
observational and interventional levels. Understanding the environmental risk factors with a 
goal toward modification and prevention may be fruitful in light of medical treatment of 
both acute and chronic DILI limited by a lack of specific therapies and antidotes currently 
available; judicious use of a potentially hepatotoxic drug in a patient with underlying risk 
factors remains the mainstay of DILI management.
Acknowledgments
Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney 
Diseases of the National Institutes of Health under award number T32DK007769.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health.
REFERENCES
1. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, 
prospective study. Hepatology 2010;52(6):2065–76. [PubMed: 20949552] 
2. Bjornsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death 
or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40(9):1095–101. [PubMed: 
16165719] 
3. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a 
prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135(6):
1924–34.e1921–24.
4. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug 
Metab Toxicol 2011;7(7):875–90. [PubMed: 21510822] 
5. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 
incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129(2):
512–21. [PubMed: 16083708] 
Stine and Chalasani Page 7
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and 
management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109(7):950–66 
[quiz: 967]. [PubMed: 24935270] 
7. Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int 
2015;35(11):2343–53. [PubMed: 26346512] 
8. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with 
substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014;147(1):96–
108.e104. [PubMed: 24681128] 
9. Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with 
combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 2013;28(1):161–7. 
[PubMed: 23020522] 
10. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver 
injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 
2010;105(11):2396–404. [PubMed: 20648003] 
11. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 889 patients with drug-
induced liver injury: the DILIN prospective study. Gastroenterology 2015;48(7):1340–52.e7.
12. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd 
edition Philadelphia: Lippincott-Williams & Wilkins; 1999.
13. Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd edition London: Elsevier/
Academic Press; 2013 p. 746.
14. FDA drug stopping rules 2009 Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/
UCM174090.pdf. Accessed April 11, 2016.
15. Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and 
beyond. Clin Gastroenterol Hepatol 2015;13(12):2173–89.e8. [PubMed: 26116527] 
16. Lindquist M VigiBase, the WHO global ICSR database system: basic facts. Drug Inform J 
2007;42:409–19.
17. Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: 
analyses of spontaneous reports to VigiBase. Drug Saf 2012;35(12):1171–82. [PubMed: 
23072620] 
18. Ampadu HH, Hoekman J, de Bruin ML, et al. Adverse drug reaction reporting in Africa and a 
comparison of individual case safety report characteristics between Africa and the rest of the 
world: analyses of spontaneous reports in vigiBase((R)). Drug Saf 2016;39(4):335–45. [PubMed: 
26754924] 
19. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting 
frequency of liver adverse events in VigiBase: unified list based on international collaborative 
work. Drug Saf 2010;33(6):503–22. [PubMed: 20486732] 
20. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-
induced hepatotoxicity. Hepatology 2002;35(4):876–82. [PubMed: 11915034] 
21. Maddrey WC. Hepatic effects of acetaminophen. Enhanced toxicity in alcoholics. J Clin 
Gastroenterol 1987;9(2):180–5. [PubMed: 3553308] 
22. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of 
alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22(3):767–73. 
[PubMed: 7657281] 
23. Draganov P, Durrence H, Cox C, et al. Alcohol-acetaminophen syndrome. Even moderate social 
drinkers are at risk. Postgrad Med 2000;107(1):189–95.
24. Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics. A 
therapeutic misadventure. Ann Intern Med 1986;104(3):399–404. [PubMed: 3511825] 
25. Lauterburg BH, Davies S, Mitchell JR. Ethanol suppresses hepatic glutathione synthesis in rats in 
vivo. J Pharmacol Exp Ther 1984;230(1):7–11. [PubMed: 6747833] 
26. Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol 
hepatotoxicity. Gut 1988;29(9):1153–7. [PubMed: 3197987] 
27. Bray GP, Mowat C, Muir DF, et al. The effect of chronic alcohol intake on prognosis and outcome 
in paracetamol overdose. Hum Exp Toxicol 1991;10(6):435–8. [PubMed: 1687856] 
Stine and Chalasani Page 8
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in 
pulmonary tuberculosis patients. J Family Med Prim Care 2015; 4(2):238–43. [PubMed: 
25949974] 
29. Altomare E, Leo MA, Lieber CS. Interaction of acute ethanol administration with acetaminophen 
metabolism and toxicity in rats fed alcohol chronically. Alcohol Clin Exp Res 1984;8(4):405–8. 
[PubMed: 6385764] 
30. Barve S, Kapoor R, Moghe A, et al. Focus on the liver: alcohol use, highly active antiretroviral 
therapy, and liver disease in HIV-infected patients. Alcohol Res Health 2010;33(3):229–36. 
[PubMed: 23584064] 
31. Kumar S, Jin M, Ande A, et al. Alcohol consumption effect on antiretroviral therapy and HIV-1 
pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol 2012;8(11):
1363–75. [PubMed: 22871069] 
32. Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in 
patients with advanced cirrhosis. Dig Dis Sci 2015;60(4):1031–5. [PubMed: 25373453] 
33. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol 
use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28(6):945–50. [PubMed: 
9672168] 
34. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity 
associated with antiretroviral combination therapy. J Infect Dis 2002; 186(1):23–31. [PubMed: 
12089658] 
35. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 
104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol 
consumption during long term follow-up. Can J Gastroenterol 1996;10(6):369–75. [PubMed: 
9193771] 
36. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a 
meta-analysis. Am J Med 1991;90(6):711–6. [PubMed: 1828327] 
37. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver 
injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44(6):1581–8. [PubMed: 
17133470] 
38. Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, et al. The role of cigarette smoking and liver 
enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. 
Tuberculosis (Edinb) 2014;94(3):299–305. [PubMed: 24793319] 
39. Czekaj P, Wiaderkiewicz A, Florek E, et al. Tobacco smoke-dependent changes in cytochrome 
P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human 
placenta. Arch Toxicol 2005;79(1):13–24. [PubMed: 15448981] 
40. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40(4): 773. 
[PubMed: 15382161] 
41. Schmidt LE, Dalhoff K. The impact of current tobacco use on the outcome of paracetamol 
poisoning. Aliment Pharmacol Ther 2003;18(10):979–85. [PubMed: 14616163] 
42. Wada T, Ueda M, Abe K, et al. Risk factor of liver disorders caused by flutamide–statistical 
analysis using multivariate logistic regression analysis. Hinyokika Kiyo 1999;45(8):521–6 [in 
Japanese]. [PubMed: 10500955] 
43. Liguori MJ, Ditewig AC, Maddox JF, et al. Comparison of TNFalpha to lipopolysaccharide as an 
inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: trovafloxacin as an 
example. Int J Mol Sci 2010;11(11): 4697–714. [PubMed: 21151465] 
44. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory 
stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 
2010;118(1):7–18. [PubMed: 20538741] 
45. Maddox JF, Amuzie CJ, Li M, et al. Bacterial- and viral-induced inflammation increases sensitivity 
to acetaminophen hepatotoxicity. J Toxicol Environ Health A 2010;73(1):58–73. [PubMed: 
19953420] 
46. Ganey PE, Luyendyk JP, Newport SW, et al. Role of the coagulation system in acetaminophen-
induced hepatotoxicity in mice. Hepatology 2007;46(4):1177–86. [PubMed: 17654741] 
Stine and Chalasani Page 9
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
47. Liu J, Sendelbach LE, Parkinson A, et al. Endotoxin pretreatment protects against the 
hepatotoxicity of acetaminophen and carbon tetrachloride: role of cytochrome P450 suppression. 
Toxicology 2000;147(3):167–76. [PubMed: 10924799] 
48. Labib R, Turkall R, Abdel-Rahman MS. Endotoxin potentiates the hepatotoxicity of cocaine in 
male mice. J Toxicol Environ Health A 2002;65(14):977–93. [PubMed: 12133232] 
49. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical 
guide. Aliment Pharmacol Ther 2013;37(12):1132–56. [PubMed: 23638982] 
50. Lu J, Jones AD, Harkema JR, et al. Amiodarone exposure during modest inflammation induces 
idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 2012;125(1):
126–33. [PubMed: 21984482] 
51. Zou W, Beggs KM, Sparkenbaugh EM, et al. Sulindac metabolism and synergy with tumor 
necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J 
Pharmacol Exp Ther 2009;331(1):114–21. [PubMed: 19638570] 
52. Tukov FF, Luyendyk JP, Ganey PE, et al. The role of tumor necrosis factor alpha in 
lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 2007; 100(1):267–80. 
[PubMed: 17698507] 
53. Cheng L, You Q, Yin H, et al. Effect of polyl: C cotreatment on halothane-induced liver injury in 
mice. Hepatology 2009;49(1):215–26. [PubMed: 19111017] 
54. Shaw PJ, Fullerton AM, Scott MA, et al. The role of the hemostatic system in murine liver injury 
induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. 
Toxicol Appl Pharmacol 2009;236(3):293–300. [PubMed: 19367693] 
55. Verrijken A, Francque S, Mertens I, et al. Prothrombotic factors in histologically proven NAFLD 
and NASH. Hepatology 2014;59(1):121–9. [PubMed: 24375485] 
56. Luyendyk JP, Maddox JF, Green CD, et al. Role of hepatic fibrin in idiosyncrasylike liver injury 
from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 2004;40(6):1342–51. [PubMed: 
15565632] 
57. Stravitz RT, Bowling R, Bradford RL, et al. Role of procoagulant microparticles in mediating 
complications and outcome of acute liver injury/acute liver failure. Hepatology 2013;58(1):304–
13. [PubMed: 23389887] 
58. Souayed N, Chennoufi M, Boughattas F, et al. Circadian variation in murine hepatotoxicity to the 
antituberculosis agent <<lsoniazide>>. Chronobiol Int 2015; 32(9):1201–10. [PubMed: 26479844] 
59. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev 
Pharmacol Toxicol 2007;47:593–628. [PubMed: 17209800] 
60. DeBruyne JP, Weaver DR, Dallmann R. The hepatic circadian clock modulates xenobiotic 
metabolism in mice. J Biol Rhythms 2014;29(4):277–87. [PubMed: 25238856] 
61. Johnson BP, Walisser JA, Liu Y, et al. Hepatocyte circadian clock controls acetaminophen 
bioactivation through NADPH-cytochrome P450 oxidoreductase. Proc Natl Acad Sci U S A 
2014;111(52):18757–62. [PubMed: 25512522] 
62. Wang T, Yang P, Zhan Y, et al. Deletion of circadian gene Per1 alleviates acute ethanol-induced 
hepatotoxicity in mice. Toxicology 2013;314(2–3):193–201. [PubMed: 24144995] 
63. Xu YQ, Zhang D, Jin T, et al. Diurnal variation of hepatic antioxidant gene expression in mice. 
PLoS One 2012;7(8):e44237. [PubMed: 22952936] 
64. Kakan X, Chen P, Zhang J. Clock gene mPer2 functions in diurnal variation of acetaminophen 
induced hepatotoxicity in mice. Exp Toxicol Pathol 2011;63(6): 581–5. [PubMed: 20472413] 
65. Boorman GA, Blackshear PE, Parker JS, et al. Hepatic gene expression changes throughout the day 
in the Fischer rat: implications for toxicogenomic experiments. Toxicol Sci 2005;86(1):185–93. 
[PubMed: 15814895] 
66. Bruckner JV, Ramanathan R, Lee KM, et al. Mechanisms of circadian rhythmicity of carbon 
tetrachloride hepatotoxicity. J Pharmacol Exp Ther 2002;300(1): 273–81. [PubMed: 11752126] 
67. Ngong JM, Waring RH. Circadian rhythms of paracetamol metabolism in healthy subjects; a 
preliminary report. Drug Metabol Drug Interact 1994; 11(4):317–30. [PubMed: 12369755] 
68. Schnell RC, Bozigian HP, Davies MH, et al. Circadian rhythm in acetaminophen toxicity: role of 
nonprotein sulfhydryls. Toxicol Appl Pharmacol 1983;71(3): 353–61. [PubMed: 6658786] 
Stine and Chalasani Page 10
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
69. Howell SR, Klaassen C. Circadian variation of hepatic UDP-glucuronic acid and the 
glucuronidation of xenobiotics in mice. Toxicol Lett 1991;57(1):73–9. [PubMed: 2048163] 
70. Martensson J The effect of fasting on leukocyte and plasma glutathione and sulfur amino acid 
concentrations. Metabolism 1986;35(2):118–21. [PubMed: 3945186] 
71. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin 
Pharmacokinet 1996;31(1):47–64. [PubMed: 8827399] 
72. Buchanan N, Eyberg C, Davis MD. Isoniazid pharmacokinetics in kwashiorkor. S Afr Med J 
1979;56(8):299–300. [PubMed: 550491] 
73. Possamai LA, McPhail MJ, Khamri W, et al. The role of intestinal microbiota in murine models of 
acetaminophen-induced hepatotoxicity. Liver Int 2015;35(3): 764–73. [PubMed: 25244648] 
74. Xue H, Xie W, Jiang Z, et al. 3,4-Dihydroxyphenylacetic acid, a microbiota-derived metabolite of 
quercetin, attenuates acetaminophen (APAP)-induced liver injury through activation of Nrf-2. 
Xenobiotica 2016;46(10):1–9. [PubMed: 26068521] 
75. Bhowmik SK, An JH, Lee SH, et al. Alteration of bile acid metabolism in pseudo germ-free rats 
[corrected]. Arch Pharm Res 2012;35(11):1969–77. [PubMed: 23212639] 
76. D’Andrea MA, Reddy GK. Health consequences among subjects involved in Gulf oil spill clean-up 
activities. Am J Med 2013;126(11):966–74. [PubMed: 24050487] 
77. Payan-Renteria R, Garibay-Chavez G, Rangel-Ascencio R, et al. Effect of chronic pesticide 
exposure in farm workers of a Mexico community. Arch Environ Occup Health 2012;67(1):22–30. 
[PubMed: 22315932] 
78. Hodgson E, Rose RL. Organophosphorus chemicals: potent inhibitors of the human metabolism of 
steroid hormones and xenobiotics. Drug Metab Rev 2006; 38(1–2):149–62. [PubMed: 16684654] 
79. Hodgson E, Rose RL. Human metabolic interactions of environmental chemicals. J Biochem Mol 
Toxicol 2007;21(4):182–6. [PubMed: 17936932] 
80. Gao H, Liu Y, Guan W, et al. Hepatotoxicity and nephrotoxicity of organic contaminants in 
wastewater-irrigated soil. Environ Sci Pollut Res Int 2015;22(5): 3748–55. [PubMed: 25263415] 
81. Cecchi A, Rovedatti MG, Sabino G, et al. Environmental exposure to organophosphate pesticides: 
assessment of endocrine disruption and hepatotoxicity in pregnant women. Ecotoxicol Environ Saf 
2012;80:280–7. [PubMed: 22494479] 
Stine and Chalasani Page 11
Clin Liver Dis. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Box 1
Environmental risk factors for drug-induced liver injury
Intrinsic
 Circadian rhythm
 Hepatic clock
 Infection
 Inflammation
 Intestinal microbiome
Extrinsic
 Alcohol consumption
 Regional geographic variation
 Smoking
 Socioeconomic status
 Environmental pollution
KEY POINTS
• In general, human data on the environment and drug-induced liver injury 
(DILI) are sparse and the majority of understanding is derived from animal 
studies of both intrinsic and idiosyncratic injury.
• Smoking can induce cytochrome P450 (CYP) enzymes but this does not 
necessarily translate into DILI.
• Alcohol consumption is a clear risk factor for hepatotoxicity from 
acetaminophen (APAP) and may predispose to injury from antituberculosis 
(anti-TB) medications but large international registries have not found an 
association between excessive alcohol consumption and DILI in general.
• Understanding of the role of infection, proinflammatory states, the hepatic 
clock, environmental pollutants, and the microbiome in predisposing an 
individual to DILI is still evolving.
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